ETNB241220C20000
- 0.00
- 0.000.00%
89bio Newsroom
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | 89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
89Bio Inc. Reports Q3 2024 Financial Results
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024
Express News | 89Bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the Enliven Phase 2B Trial in Mash Patients at Aasld the Liver Meeting® 2024
89bio (ETNB) Receives a Hold From Oppenheimer
Reported Earlier, 89bio Prices Upsized $125M Public Offering Of 11,455,882 Common Stock At $8.50/Share And Pre-Funded Warrants
89bio Drops 2%, Prices $125M Stock Offering
89bio Offering Is Expected to Close Around Nov. 14 >ETNB
89bio Prices $125.0M Upsized Public Offering of Stock, Warrants >ETNB
Express News | 89Bio Inc - Commences $100 Million Public Offering
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Express News | 89Bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Evercore Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $33
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)
H.C. Wainwright Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $29
HC Wainwright & Co. Reiterates Buy on 89bio, Maintains $29 Price Target
Positive Outlook for 89bio Amid Promising Developments in MASH Clinical Programs
89bio's Pegozafermin: A Promising Best-in-Class Contender in NASH Treatment